Navigation Links
Moffitt Cancer Center signs licensing agreement with Proteacel, LLC
Date:3/18/2010

Tampa, FL (March 18, 2010) Moffitt Cancer Center and Proteacel LLC announced today that they have entered a licensing agreement under which Proteacel has acquired the exclusive rights to the PORE technology for delivery of genes into cells.

Genes are the instructions that build cells. Defects in these genes cause disease, such as cancer. In order to understand how these genes work and their involvement in a disease process, researchers must study and modify them. The most common way to study gene function is to transfer the gene into cells. Transfection is the process of introducing foreign DNA, or genes, into cells. This fundamental process is critical in conducting medical research. However, low rates of transfection and high levels of cell death currently create bottlenecks.

Under the direction of Dr. Deepak Agrawal, Moffitt researchers have developed a proprietary technology that dramatically improves the functionality and performance of transfection technology. The patented Perforation Optimization and Repair Enhancement, or PORE, solves a number of immediate problems in the use of transfection by creating a higher level of efficiency and cell viability. This is particularly valuable for stem cells and primary cells that are the most medically relevant and the most difficult to transfect.

"I am very pleased that the PORE technology will be made available to researchers throughout the world," Agrawal said. "We believe PORE will fuel biological discovery by allowing more effective use of stem cells and primary cells for research, drug discovery and development of cell therapies."

"Proteacel's initial business activity will have Proteacel contracting to transfect specific hard to transfect cell lines with identified DNA," said Dr. Joseph Zendegui, president and chief operating officer of Proteacel. "Target customers for this service will be academic institutions and biotechnology companies in the biomedical research field. Using PORE as our technology base, we will expand our efforts into development and commercialization of drug discovery, cell differentiation assays."

"We are excited to see this technology move from the research labs here at Moffitt Cancer Center into the capable hands of Proteacel for the continuation of its development," said Ray Carpenter of Moffitt's Office of Technology Management and Commercialization. "Further, our office will remain focused on bridging entrepreneurs and Moffitt's faculty to cultivate local start-up company opportunities."

Under the terms of the License Agreement, Proteacel will pay Moffitt license fees, milestone payments and royalties on sales of PORE products and services.


'/>"/>

Contact: Michelle Foley
Michelle.Foley@moffitt.org
813-745-1505
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related biology news :

1. Could regulating intestinal inflammation prevent colon cancer?
2. Blocking cancer in its path: New cellular defect discovered
3. UAB oncologists: HPV vaccine protects from cancer recurrence
4. 2 at 1 stroke -- how cells protect themselves from cancer
5. 5th Annual Szent-Györgyi Prize for Progress in Cancer Research awarded
6. A golden bullet for cancer
7. Preventing gastric cancer with antibiotics
8. Berkeley scientists find new way to get physical in the fight against cancer
9. VAI researchers develop tool to help study prostate cancer
10. LSUHSC researcher finds first inherited prostate cancer genetic mutation in African-American men
11. Breast cancer drug fulvestrant appears more effective in the presence of CK8 and CK18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
(Date:4/13/2017)... SANTA MONICA, Calif. , April 13, 2017 /PRNewswire/ ... New York will feature emerging and ... Innovation Summits. Both Innovation Summits will run alongside the ... variety of speaker sessions, panels and demonstrations focused on ... east coast,s largest advanced design and manufacturing event will ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Biology News(10 mins):
(Date:7/17/2017)... Yorba Linda, Ca (PRWEB) , ... July 17, ... ... highly heterogeneous and are characterized by a wide range of overlapping clinical features. ... pace of discovery in the field of NDD research and testing. , ...
(Date:7/17/2017)... ... July 17, 2017 , ... DuPont Pioneer today ... website (openinnovation.pioneer.com) dedicated to connecting third-party innovators with DuPont Pioneer scientists ... breeding, enabling technologies, biologicals and digital solutions. , “DuPont Pioneer is building on ...
(Date:7/15/2017)... ... 15, 2017 , ... Cuvette manufacturer FireflySci has been making many ... people at FFS have learned that their biggest asset was their amazing customer base. ... launch new products to meet the changing needs of scientists at a rapid pace. ...
(Date:7/14/2017)... ... July 13, 2017 , ... ... verification test kit has received US FDA 510 (k) clearance for use on ... matrix, evaluates D-Dimer. Each VALIDATE® D-Dimer kit, prepared using the CLSI EP06-A “equal ...
Breaking Biology Technology: